| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 |
| filingDate |
2020-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2022553833-A |
| titleOfInvention |
Salts and Forms of Estrogen Receptor Modulators |
| abstract |
The salts and forms of Compound A described herein are estrogen receptor alpha modulators. Such salts and/or forms are useful for treating estrogen receptor alpha dependent and/or estrogen receptor alpha mediated diseases or conditions, including conditions characterized by excessive cell proliferation such as breast cancer. can be. |
| priorityDate |
2019-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |